Filing Overview
Registrant: Priveterra Acquisition Corp., a special purpose acquisition company pursuing a business combination with AEON Biopharma, Inc. The Form 8-K was filed June 6, 2023, under Item 8.01, Other Events.
Business Context and Reporting Period
The filing concerns the special meeting of Priveterra stockholders to vote on the proposed business combination with AEON Biopharma. The meeting was originally scheduled for June 6, 2023, and was adjourned to June 9, 2023, at 12:00 p.m. Eastern Time, to allow additional time to engage with stockholders.
Financial Metrics and Capital Structure
This filing does not provide financial statements, revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics. It identifies Priveterra’s publicly traded units, Class A common stock, and redeemable warrants, but does not report changes in their financial terms.
Material Changes and Transaction Updates
- The special meeting was adjourned from June 6 to June 9, 2023.
- The virtual meeting access address was corrected to www.virtualshareholdermeeting.com/PMGM2023SM.
- Priveterra supplemented its May 12, 2023 definitive proxy statement with updated information regarding the adjournment.
- There was no change to the meeting location, April 11, 2023 record date, redemption deadline, or other proposals.
- Stockholders who previously voted and do not wish to change their vote need not take further action. Eligible stockholders may withdraw redemption requests before the rescheduled meeting by requesting return of their shares from the transfer agent.
Outlook, Risks, and Other Considerations
The filing does not provide financial guidance or operating forecasts. It includes customary forward-looking statement disclaimers and refers investors to the risk factors and cautionary disclosures in Priveterra’s definitive proxy statement, related registration statement, IPO prospectus, and other SEC filings. Completion of the proposed business combination remains subject to stockholder approval and other applicable conditions described in the transaction documents.
Key Facts for Investor Verification
- Confirm the outcome of the June 9, 2023 special meeting and whether the business combination with AEON Biopharma was approved and completed.
- Review the definitive proxy statement and related registration statement for transaction terms, redemption levels, dilution, pro forma ownership, and closing conditions.
- Verify any subsequent changes to the redemption deadline, meeting procedures, or transaction timetable.
- Review AEON Biopharma’s financial statements, liquidity position, operating results, and risk factors in the applicable transaction filings.